FDA approves Protalix's (PLX) Gaucher Disease drug Elelyso
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
The FDA approved Protalix's (NYSE: PLX) Gaucher Disease drug Elelyso
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA places clinical hold on Regenxbio's RGX-121 gene therapy for Hunter Syndrome
- Blue Star Gold reports phase 2 drilling results at Nutaaq target
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
